EA029577B1 - Клетки-предшественники мезодермальной линии - Google Patents
Клетки-предшественники мезодермальной линии Download PDFInfo
- Publication number
- EA029577B1 EA029577B1 EA201391773A EA201391773A EA029577B1 EA 029577 B1 EA029577 B1 EA 029577B1 EA 201391773 A EA201391773 A EA 201391773A EA 201391773 A EA201391773 A EA 201391773A EA 029577 B1 EA029577 B1 EA 029577B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- tissue
- patient
- bone
- present
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 167
- 210000001519 tissue Anatomy 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 76
- 102000005962 receptors Human genes 0.000 claims description 41
- 108020003175 receptors Proteins 0.000 claims description 41
- 230000006378 damage Effects 0.000 claims description 34
- 210000000988 bone and bone Anatomy 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 29
- 239000002243 precursor Substances 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 102000004890 Interleukin-8 Human genes 0.000 claims description 18
- 108090001007 Interleukin-8 Proteins 0.000 claims description 18
- 229940096397 interleukin-8 Drugs 0.000 claims description 17
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 17
- 239000006166 lysate Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 102000004125 Interleukin-1alpha Human genes 0.000 claims description 16
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- 101100420928 Oryza sativa subsp. japonica SE14 gene Proteins 0.000 claims description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 15
- 210000005003 heart tissue Anatomy 0.000 claims description 15
- 230000002207 retinal effect Effects 0.000 claims description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 14
- 208000010392 Bone Fractures Diseases 0.000 claims description 13
- 206010017076 Fracture Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 13
- 102000019034 Chemokines Human genes 0.000 claims description 12
- 108010012236 Chemokines Proteins 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 12
- 210000005087 mononuclear cell Anatomy 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 11
- 208000020084 Bone disease Diseases 0.000 claims description 10
- 102000009410 Chemokine receptor Human genes 0.000 claims description 10
- 108050000299 Chemokine receptor Proteins 0.000 claims description 10
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 8
- 229960003130 interferon gamma Drugs 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 7
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- -1 SI117 (ο-Κίί) Proteins 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000008439 repair process Effects 0.000 claims description 6
- 102000012334 Integrin beta4 Human genes 0.000 claims description 5
- 108010022238 Integrin beta4 Proteins 0.000 claims description 5
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims description 5
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 5
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 210000002536 stromal cell Anatomy 0.000 claims description 5
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 5
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 4
- 108010024212 E-Selectin Proteins 0.000 claims description 4
- 102100023471 E-selectin Human genes 0.000 claims description 4
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 4
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 4
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 4
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims description 4
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims description 4
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 claims description 4
- 206010031240 Osteodystrophy Diseases 0.000 claims description 4
- 108010035766 P-Selectin Proteins 0.000 claims description 4
- 102100023472 P-selectin Human genes 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 102000010790 Interleukin-3 Receptors Human genes 0.000 claims description 3
- 108010038452 Interleukin-3 Receptors Proteins 0.000 claims description 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 3
- 108010092694 L-Selectin Proteins 0.000 claims description 3
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 3
- 208000016738 bone Paget disease Diseases 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000003716 mesoderm Anatomy 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 101710145634 Antigen 1 Proteins 0.000 claims description 2
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000009283 Craniosynostoses Diseases 0.000 claims description 2
- 206010049889 Craniosynostosis Diseases 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 101710167839 Morphogenetic protein Proteins 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000008558 Osteophyte Diseases 0.000 claims description 2
- 208000027067 Paget disease of bone Diseases 0.000 claims description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 2
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims description 2
- 208000005688 Salter-Harris Fractures Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 230000002281 colonystimulating effect Effects 0.000 claims description 2
- 201000010934 exostosis Diseases 0.000 claims description 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims description 2
- 208000018578 heart valve disease Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Proteins 0.000 claims description 2
- 230000000849 parathyroid Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 210000005167 vascular cell Anatomy 0.000 claims description 2
- 102100021942 C-C motif chemokine 28 Human genes 0.000 claims 2
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010049933 Hypophosphatasia Diseases 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 206010061363 Skeletal injury Diseases 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 230000002988 nephrogenic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 32
- 210000001772 blood platelet Anatomy 0.000 description 27
- 239000002609 medium Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 229920001917 Ficoll Polymers 0.000 description 5
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 4
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000014306 paracrine signaling Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003800 Selectins Human genes 0.000 description 3
- 108090000184 Selectins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101001082567 Caenorhabditis elegans Hypoxia-inducible factor 1 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010061068 Congenital knee deformity Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000012085 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 208000006367 Essential Osteolysis Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000019683 Gorham-Stout disease Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001046529 Homo sapiens Mevalonate kinase Proteins 0.000 description 1
- 101000990990 Homo sapiens Midkine Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 241000538132 Moya Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000000175 Nail-Patella Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000009065 Netrin-1 Human genes 0.000 description 1
- 108010074223 Netrin-1 Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000053521 human MDK Human genes 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1111503.7A GB201111503D0 (en) | 2011-07-06 | 2011-07-06 | Heart failure (HF) MSC subtype |
| GBGB1111500.3A GB201111500D0 (en) | 2011-07-06 | 2011-07-06 | Wet age-related macular degeneration MSC subtype |
| GBGB1111509.4A GB201111509D0 (en) | 2011-07-06 | 2011-07-06 | Orthopedic MSC subtype |
| GBGB1111505.2A GB201111505D0 (en) | 2011-07-06 | 2011-07-06 | MI MSC subtype |
| PCT/GB2012/051600 WO2013005053A2 (en) | 2011-07-06 | 2012-07-06 | Progenitor cells of mesodermal lineage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201391773A1 EA201391773A1 (ru) | 2014-11-28 |
| EA029577B1 true EA029577B1 (ru) | 2018-04-30 |
Family
ID=46513785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391773A EA029577B1 (ru) | 2011-07-06 | 2012-07-06 | Клетки-предшественники мезодермальной линии |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10472609B2 (enExample) |
| EP (1) | EP2729562B1 (enExample) |
| JP (2) | JP6607675B2 (enExample) |
| CN (2) | CN104508124B (enExample) |
| AU (2) | AU2012279995C1 (enExample) |
| CA (1) | CA2840307C (enExample) |
| CY (1) | CY1120646T1 (enExample) |
| DK (1) | DK2729562T3 (enExample) |
| EA (1) | EA029577B1 (enExample) |
| ES (1) | ES2675693T3 (enExample) |
| HR (1) | HRP20181152T1 (enExample) |
| HU (1) | HUE039236T2 (enExample) |
| IL (2) | IL230071B (enExample) |
| LT (1) | LT2729562T (enExample) |
| MY (1) | MY185016A (enExample) |
| PL (1) | PL2729562T3 (enExample) |
| PT (1) | PT2729562T (enExample) |
| SG (1) | SG10201605518XA (enExample) |
| WO (1) | WO2013005053A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087868A1 (en) | 2010-10-08 | 2012-04-12 | Gabriele Todd | Nanoparticle-loaded cells |
| PL2782555T3 (pl) * | 2011-11-23 | 2019-09-30 | Cell Therapy Limited | Żel z lizatem płytek krwi |
| JP6615753B2 (ja) * | 2013-10-04 | 2019-12-04 | レジニアス リミテッド | 細胞療法のためのバイオマーカー |
| GB201408712D0 (en) * | 2014-05-16 | 2014-07-02 | Univ Leuven Kath | Mesodermal progenitor cells |
| GB201410504D0 (en) | 2014-06-12 | 2014-07-30 | Cell Therapy Ltd | Immuno-modulaltory progenitor (IMP) cell |
| CN107076745A (zh) * | 2014-08-29 | 2017-08-18 | 贝克顿·迪金森公司 | 在受试者中获得结核病评价的方法和组合物 |
| JP2018512061A (ja) * | 2015-02-20 | 2018-05-10 | ナショナル ヤン−ミン ユニバーシティ | 骨関節炎処置のための間葉幹細胞の使用 |
| EP3091084A1 (en) * | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Methods for assessing the purity of a mesenchymal stem cells preparation |
| GB201513996D0 (en) | 2015-08-07 | 2015-09-23 | Cell Therapy Ltd | Immuno-oncology mesodermal progenitor (IOMP) cell |
| JP6830893B2 (ja) | 2015-09-11 | 2021-02-17 | アステラス製薬株式会社 | 腎前駆細胞を製造する方法 |
| GB201518263D0 (en) | 2015-10-15 | 2015-12-02 | Oxford Bioelectronics Ltd | Method |
| CN105483206B (zh) * | 2016-01-06 | 2019-09-13 | 北京汉氏联合生物技术股份有限公司 | 一种用vcam-1检测msc促内皮细胞增殖能力的方法 |
| US11066648B2 (en) * | 2016-08-29 | 2021-07-20 | Hackensack University Medical Center | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans |
| CA3033750A1 (en) * | 2016-08-29 | 2018-03-08 | Hackensack University Medical Center | Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells |
| CN112004923A (zh) | 2017-11-22 | 2020-11-27 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| JP7009977B2 (ja) * | 2017-12-25 | 2022-01-26 | 国立大学法人東海国立大学機構 | 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム |
| CN108715833B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种负载血小板裂解液的微球制备方法 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| US12310989B2 (en) * | 2018-11-14 | 2025-05-27 | Onderzoeks- En Ontwikkelingsfonds Rode Kruis-Vlaanderen | Methods for preparing platelet releasate |
| CN109329270A (zh) * | 2018-11-19 | 2019-02-15 | 成都清科生物科技有限公司 | 一种静脉回输用间充质干细胞保存液及其制备方法 |
| GB201900554D0 (en) | 2019-01-15 | 2019-03-06 | Cell Therapy Ltd | Mesodermal killer (mk) cell |
| US20230047325A1 (en) * | 2019-01-15 | 2023-02-16 | Cell Therapy Limited | Mesodermal killer (mk) cell |
| WO2020157660A1 (en) * | 2019-01-28 | 2020-08-06 | Mesoblast International Sárl | Method for treating or preventing gastrointestinal bleeding |
| EP3968992A4 (en) * | 2019-05-15 | 2023-06-21 | Stemcyte, Inc. | PACKAGING AND SHIPPING HIGH CONCENTRATION CELLS |
| CN110237094B (zh) * | 2019-07-30 | 2023-10-03 | 天晴干细胞股份有限公司 | 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007058404A1 (en) * | 2005-11-16 | 2007-05-24 | Rnl Bio Co., Ltd. | Multipotent stem cells derived from human adipose tissue and cellular therapeutic agents comprising the same |
| WO2009069991A2 (en) * | 2007-11-30 | 2009-06-04 | Rnl Bio Co., Ltd. | Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose |
| WO2010021412A1 (ja) * | 2008-08-22 | 2010-02-25 | 財団法人ヒューマンサイエンス振興財団 | 脳梗塞治療材及び脳組織再生方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801537D0 (sv) | 1988-04-26 | 1988-04-26 | Ellco Food Ab | Cellodlingsmedium samt forfarande for dess framstellning |
| RU2138162C1 (ru) | 1997-04-17 | 1999-09-27 | Суханов Владимир Александрович | Способ криоконсервации богатой тромбоцитами плазмы |
| EP1028737B1 (en) | 1997-07-03 | 2007-04-04 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells from peripheral blood |
| WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| EP1082410B1 (en) | 1998-05-29 | 2007-08-01 | Osiris Therapeutics, Inc. | Human cd45+ and/or fibroblast + mesenchymal stem cells |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| DK1226233T3 (da) | 1999-08-05 | 2011-10-03 | Abt Holding Co | Multipotente voksne stamceller og fremgangsmåder til isolering heraf |
| AUPR703601A0 (en) | 2001-08-15 | 2001-09-06 | Peter Maccallum Cancer Institute, The | Identification and isolation of somatic stem cells and uses thereof |
| JP2003055237A (ja) * | 2001-08-15 | 2003-02-26 | Japan Science & Technology Corp | 骨再生促進剤 |
| DE60314602T2 (de) | 2002-02-19 | 2008-02-28 | Medipost, Co., Ltd. | Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe |
| KR100534215B1 (ko) | 2003-11-11 | 2005-12-08 | (주)히스토스템 | 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법 |
| DE102005011568A1 (de) | 2004-04-13 | 2005-11-17 | Man Roland Druckmaschinen Ag | Produktionsverfahren für eine Prägeeinrichtung in einer Bogendruckmaschine |
| US20090047257A1 (en) | 2004-07-20 | 2009-02-19 | Case Western Reserve University | Novel cell populations and uses thereof |
| AU2005287855B2 (en) | 2004-09-24 | 2011-06-16 | Mesoblast, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) |
| US20080260694A1 (en) | 2004-09-24 | 2008-10-23 | Angioblast Systems, Inc. | Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof |
| KR101617319B1 (ko) | 2005-04-12 | 2016-05-02 | 메소블라스트, 아이엔씨. | 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리 |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| ES2415855T3 (es) | 2006-01-13 | 2013-07-29 | Osiris Therapeutics, Inc. | Células troncales mesenquimatosas que expresan el receptor de TNF |
| EP1845154A1 (en) | 2006-04-12 | 2007-10-17 | RNL Bio Co., Ltd. | Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same |
| US20100111910A1 (en) | 2006-07-12 | 2010-05-06 | Angioblast Systems, Inc. | Treatment of excessive neovascularization |
| US20090253151A1 (en) | 2006-09-01 | 2009-10-08 | Stempeutics Research Private Limited | Self-Renewing Master Adult Pluripotent Stem Cells |
| WO2008097828A2 (en) | 2007-02-02 | 2008-08-14 | St. Jude Children's Research Hospital | Method for isolating mesenchymal stromal cells |
| WO2008129563A2 (en) | 2007-04-23 | 2008-10-30 | Stempeutics Research Private Limited, | Human mesenchymal stem cells and preparation thereof |
| US20090053182A1 (en) | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
| US9095562B2 (en) * | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
| EP2014294A1 (en) | 2007-07-13 | 2009-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of CD200 as a mesenchymal stem cells marker |
| WO2009044943A1 (en) | 2007-10-01 | 2009-04-09 | Seoul National University Industry Foundation | Various human dental stem cells having a mineralization ability and the method for culturing them |
| WO2009061024A1 (en) | 2007-11-09 | 2009-05-14 | Rnl Bio Co., Ltd | Method for isolating and culturing adult stem cells derived from human amniotic epithelium |
| EP2297305A4 (en) | 2008-05-15 | 2013-03-13 | Univ Miami | ISOLATION OF STEM CELL PROCESSORS AND EXPANSION UNDER NON-TERMS OF CONDITION |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| EP2321408A4 (en) | 2008-08-04 | 2013-04-17 | Allocure Inc | MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE |
| US9090678B2 (en) | 2008-08-18 | 2015-07-28 | Mesoblast, Inc. | Monoclonal antibody STRO-4 |
| EP2334785B2 (en) | 2008-09-16 | 2019-08-14 | Mayo Foundation For Medical Education And Research | Compositions containing platelet contents |
| EP2186883A1 (en) | 2008-11-04 | 2010-05-19 | Fresenius Medical Care | An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney |
| KR102011609B1 (ko) | 2008-11-20 | 2019-08-16 | 메소블라스트, 아이엔씨. | 췌장 기능장애를 치료 또는 예방하는 방법 |
| US20120020937A1 (en) | 2009-04-28 | 2012-01-26 | Anterogen Co., Ltd. | Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas |
| EP2488187A4 (en) | 2009-10-13 | 2014-03-26 | Allocure Inc | ASSAY FOR PREDICTING THE THERAPEUTIC EFFECT OF MECHANICAL CYCLES AND METHOD OF USE THEREOF |
| ES2358146B1 (es) | 2009-10-22 | 2012-03-23 | Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla | Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis. |
| US20110123498A1 (en) | 2009-10-30 | 2011-05-26 | Christof Westenfelder | Mesenchymal stromal cell populations and methods of using same |
| CN102048756B (zh) | 2009-11-04 | 2014-02-19 | 中国医学科学院基础医学研究所 | 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途 |
| WO2011068792A2 (en) | 2009-12-01 | 2011-06-09 | The Regents Of The University Of California | Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells |
| EP2506867B1 (en) * | 2009-12-02 | 2014-10-08 | Cardio3 Biosciences S.A. | Pharmaceutical compositions for the stimulation of stem cells. |
| KR101871472B1 (ko) | 2010-07-02 | 2018-06-27 | 메소블라스트, 아이엔씨. | 이식편대숙주 질환의 치료 방법 |
| JP6061345B2 (ja) | 2010-08-27 | 2017-01-18 | ユニヴァーシティ・オヴ・マイアミ | 心臓修復のための骨髄由来ｃｄ２７１前駆細胞 |
| US20120087868A1 (en) | 2010-10-08 | 2012-04-12 | Gabriele Todd | Nanoparticle-loaded cells |
| ES2384790B1 (es) | 2010-12-10 | 2013-05-20 | Instituto De Salud Carlos Iii | Células madre mesenquimales aisladas a partir de sangre periférica. |
| US20120288480A1 (en) | 2011-02-22 | 2012-11-15 | Taipei Medical University | Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications |
| CN102078644A (zh) * | 2011-03-08 | 2011-06-01 | 吉林大学 | 一种简便高效的自体富血小板血浆提取装置及提取方法 |
| SG194930A1 (en) | 2011-05-19 | 2013-12-30 | Mesoblast Inc | Methods for treating obesity and/or metabolic syndrome |
| CN103826646A (zh) | 2011-06-03 | 2014-05-28 | 麦瑟布莱斯特公司 | 治疗中风的影响的方法 |
| CN109276706A (zh) | 2011-06-03 | 2019-01-29 | 麦瑟布莱斯特公司 | 治疗或预防神经性疾病的方法 |
| WO2013003899A1 (en) | 2011-07-04 | 2013-01-10 | Mesoblast, Inc | Methods of treating or preventing rheumatic disease |
| CN108635377B (zh) | 2011-09-09 | 2022-06-24 | 麦瑟布莱斯特公司 | 增加成骨细胞功能的方法 |
| JP6348848B2 (ja) | 2012-02-13 | 2018-06-27 | ガミダ セル リミテッド | 間葉系幹細胞の増殖 |
| US20150064141A1 (en) | 2012-04-05 | 2015-03-05 | The Regents Of The University Of California | Regenerative sera cells and mesenchymal stem cells |
| US20130273011A1 (en) | 2012-04-17 | 2013-10-17 | Medistem, Inc. | Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome |
-
2012
- 2012-07-06 EP EP12735321.7A patent/EP2729562B1/en active Active
- 2012-07-06 US US14/130,840 patent/US10472609B2/en active Active
- 2012-07-06 HR HRP20181152TT patent/HRP20181152T1/hr unknown
- 2012-07-06 MY MYPI2014000615A patent/MY185016A/en unknown
- 2012-07-06 JP JP2014517958A patent/JP6607675B2/ja active Active
- 2012-07-06 AU AU2012279995A patent/AU2012279995C1/en active Active
- 2012-07-06 DK DK12735321.7T patent/DK2729562T3/en active
- 2012-07-06 PT PT127353217T patent/PT2729562T/pt unknown
- 2012-07-06 CN CN201280033446.3A patent/CN104508124B/zh active Active
- 2012-07-06 ES ES12735321.7T patent/ES2675693T3/es active Active
- 2012-07-06 LT LTEP12735321.7T patent/LT2729562T/lt unknown
- 2012-07-06 HU HUE12735321A patent/HUE039236T2/hu unknown
- 2012-07-06 SG SG10201605518XA patent/SG10201605518XA/en unknown
- 2012-07-06 WO PCT/GB2012/051600 patent/WO2013005053A2/en not_active Ceased
- 2012-07-06 CN CN201710962767.6A patent/CN107746830A/zh active Pending
- 2012-07-06 CA CA2840307A patent/CA2840307C/en active Active
- 2012-07-06 PL PL12735321T patent/PL2729562T3/pl unknown
- 2012-07-06 EA EA201391773A patent/EA029577B1/ru not_active IP Right Cessation
-
2013
- 2013-12-22 IL IL230071A patent/IL230071B/en active IP Right Review Request
-
2017
- 2017-06-30 AU AU2017204559A patent/AU2017204559A1/en not_active Abandoned
- 2017-07-26 JP JP2017144116A patent/JP2017225451A/ja active Pending
-
2018
- 2018-07-16 CY CY181100736T patent/CY1120646T1/el unknown
-
2019
- 2019-01-24 IL IL264455A patent/IL264455A/en unknown
- 2019-10-08 US US16/596,301 patent/US10829739B2/en active Active
-
2020
- 2020-10-07 US US17/065,335 patent/US11873513B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007058404A1 (en) * | 2005-11-16 | 2007-05-24 | Rnl Bio Co., Ltd. | Multipotent stem cells derived from human adipose tissue and cellular therapeutic agents comprising the same |
| WO2009069991A2 (en) * | 2007-11-30 | 2009-06-04 | Rnl Bio Co., Ltd. | Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose |
| WO2010021412A1 (ja) * | 2008-08-22 | 2010-02-25 | 財団法人ヒューマンサイエンス振興財団 | 脳梗塞治療材及び脳組織再生方法 |
Non-Patent Citations (17)
| Title |
|---|
| ABDALLAH B M, KASSEM M: "Human mesenchymal stem cells: from basic biology to clinical applications.", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 15, no. 2, 1 January 2008 (2008-01-01), GB, pages 109 - 116, XP002505627, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3303067 * |
| ADRIANA L�PEZ PONTE, MARAIS EMELINE, GALLAY NATHALIE, LANGONN� ALAIN, DELORME BRUNO, H�RAULT OLIVIER, CHARBORD PIERRE, DOMENECH JO: "The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities", STEM CELLS, ALPHAMED PRESS, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 1737 - 1745, XP055050706, ISSN: 10665099, DOI: 10.1634/stemcells.2007-0054 * |
| ANDRIELLE CASTILHO-FERNANDES; DANILO CANDIDO DE ALMEIDA; APARECIDA MARIA FONTES; FERNANDA URSOLI FERREIRA MELO; VIRGÍNIA PICANÇO-C: "Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells", EXPERIMENTAL AND MOLECULAR PATHOLOGY., ACADEMIC PRESS., US, vol. 91, no. 3, US, pages 664 - 672, XP028111727, ISSN: 0014-4800, DOI: 10.1016/j.yexmp.2011.09.002 * |
| BASEM M. ABDALLAH, KASSEM MOUSTAPHA: "The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: Current status and future perspectives", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC., vol. 218, no. 1, 1 January 2009 (2009-01-01), pages 9 - 12, XP055056394, ISSN: 00219541, DOI: 10.1002/jcp.21572 * |
| BUEHRING HANS-JOERG; BATTULA VENKATA LOKESH; TREML SABRINA; SCHEWE BERNHARD; KANZ LOTHAR; VOGEL WICHARD: "Novel markers for the prospective isolation of human MSC", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES., US, 16 September 2006 (2006-09-16), US, pages 262 - 271, XP009109140, ISSN: 0077-8923 * |
| CARRANCIO, S. ; LOPEZ-HOLGADO, N. ; SANCHEZ-GUIJO, F.M. ; VILLARON, E. ; BARBADO, V. ; TABERA, S. ; DIEZ-CAMPELO, M. ; BLANCO, J. : "Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC., US, vol. 36, no. 8, 1 August 2008 (2008-08-01), US, pages 1014 - 1021, XP022940505, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2008.03.012 * |
| CATHERINE M KOLF, ELIZABETH CHO, ROCKY S TUAN: "Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 19 February 2007 (2007-02-19), GB, pages 204 - 204-10, XP008146968, ISSN: 1478-6354, DOI: 10.1186/ar2116 * |
| DANUTA JAROCHA, LUKASIEWICZ EWA, MAJKA MARCIN: "Adventage of mesenchymal stem cells (MSC) expansion directly from purified bone marrow CD105+ and CD271+ cells.", FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, vol. 46, no. 3, XP055052371, ISSN: 02398508, DOI: 10.2478/v10042-008-0046-z * |
| DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 October 2010 (2010-10-01), LIU QUAN-HUA , GE JIAN, LIU KAI-YAN: "[Are CD133 and CD271 useful in positive selection to enrich umbilical cord blood mesenchymal stem cells?].", XP002693611 * |
| GISELLE CHAMBERLAIN, KARINA WRIGHT, ANTAL ROT, BRIAN ASHTON, JIM MIDDLETON: "Murine Mesenchymal Stem Cells Exhibit a Restricted Repertoire of Functional Chemokine Receptors: Comparison with Human", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 3, no. 8, 1 August 2008 (2008-08-01), US, pages e2934.1 - e2934.6, XP002622569, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0002934 * |
| HATIM HEMEDA, JAKOB MARK, LUDWIG ANNA-KRISTIN, GIEBEL BERND, LANG STEPHAN, BRANDAU SVEN: "Interferon-γ and Tumor Necrosis Factor-α Differentially Affect Cytokine Expression and Migration Properties of Mesenchymal Stem Cells", STEM CELLS AND DEVELOPMENT, vol. 19, no. 5, 1 May 2010 (2010-05-01), pages 693 - 706, XP055056178, ISSN: 15473287, DOI: 10.1089/scd.2009.0365 * |
| HOLZWARTH CHRISTINA; VAEGLER MARTIN; GIESEKE FRIEDERIKE; PFISTER STEFAN M; HANDGRETINGER RUPERT; KERST GUNTER; MÜLLER INGO: "Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells", BMC CELL BIOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 28 January 2010 (2010-01-28), GB, pages 11, XP021065781, ISSN: 1471-2121 * |
| LIU, H. ; XUE, W. ; GE, G. ; LUO, X. ; LI, Y. ; XIANG, H. ; DING, X. ; TIAN, P. ; TIAN, X.: "Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1@a in MSCs", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, AMSTERDAM, NL, vol. 401, no. 4, 29 October 2010 (2010-10-29), AMSTERDAM, NL, pages 509 - 515, XP027567795, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2010.09.076 * |
| MARIA ESTER BERNARDO, FRANCO LOCATELLI AND WILLEM E. FIBBE: "Mesenchymal stromal cells.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES., US, vol. 1176, 1 September 2009 (2009-09-01), US, pages 101 - 117, XP008156034, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2009.04607.x * |
| NAGHMEH AHMADIAN KIA; AHMAD REZA BAHRAMI; MARZIEH EBRAHIMI; MARYAM M. MATIN; ZEINAB NESHATI; MAHMOOD RAIS ALMOHADDESIN; NASER AGHD: "Comparative Analysis of Chemokine Receptor's Expression in Mesenchymal Stem Cells Derived from Human Bone Marrow and Adipose Tissue", JOURNAL OF MOLECULAR NEUROSCIENCE, HUMANA PRESS INC, NEW YORK, vol. 44, no. 3, 12 October 2010 (2010-10-12), New York, pages 178 - 185, XP019912023, ISSN: 1559-1166, DOI: 10.1007/s12031-010-9446-6 * |
| WAGNER W, HO A D: "Mesenchymal stem cell preparations--comparing apples and oranges", STEM CELL REVIEWS, HUMANA PRESS INC., US, vol. 3, no. 4, 1 December 2007 (2007-12-01), US, pages 239 - 248, XP002545736, ISSN: 1550-8943, DOI: 10.1007/s12015-007-9001-1 * |
| YAOJIONG WU; ROBERT C. H. ZHAO: "The Role of Chemokines in Mesenchymal Stem Cell Homing to Myocardium", STEM CELL REVIEWS AND REPORTS, HUMANA PRESS INC, NEW YORK, vol. 8, no. 1, 25 June 2011 (2011-06-25), New York, pages 243 - 250, XP035019891, ISSN: 1558-6804, DOI: 10.1007/s12015-011-9293-z * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11873513B2 (en) | Progenitor cells of mesodermal lineage | |
| JP6185657B2 (ja) | 免疫調節前駆（ｉｍｐ）細胞 | |
| ES2432744T3 (es) | Células del tejido adiposo extramedular y sus aplicaciones en la reconstitución del tejido cardiaco | |
| EP3154599B1 (en) | Hybrid composition | |
| US20150246079A1 (en) | Immune privileged and modulatory progenitor cells | |
| KR20180057614A (ko) | 면역-종양학 중배엽 전구체(iomp) 세포 | |
| CN113383069B (zh) | 使用转化的t细胞培养脐带血来源的自然杀伤细胞的方法 | |
| WO2014193895A1 (en) | Ex vivo perfusion of donor organs prior to transplantation using mesenchymal stem cells | |
| CN120769904A (zh) | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 | |
| HK1198047A (en) | Progenitor cells of mesodermal lineage | |
| HK1198047B (en) | Progenitor cells of mesodermal lineage | |
| NZ620283B2 (en) | Progenitor cells of mesodermal lineage | |
| CN120866362A (zh) | 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM BY KZ KG TJ TM |